{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:03:52Z","timestamp":1747184632479,"version":"3.40.5"},"reference-count":8,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ibrutinib is an oral inhibitor of Bruton tyrosine kinase approved for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and refractory Waldenstrom's disease. It increases progression\u2010free survival, overall survival, response rate. The most frequent adverse reactions, are increased risk in of bleeding and atrial fibrillation, but several reports of more dangerous rhythm disturbances have been recently reported in literature. A case of a patient with refractory Waldenstrom's disease, who developed ventricular fibrillation while taking ibrutinib, is reported, along with a concise literature review.<\/jats:p>","DOI":"10.1111\/ejh.13290","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T10:49:52Z","timestamp":1562669392000},"page":"442-443","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sudden ventricular fibrillation and death during ibrutinib therapy\u2014A case report"],"prefix":"10.1111","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-4280","authenticated-orcid":false,"given":"Paolo","family":"Bernardeschi","sequence":"first","affiliation":[{"name":"Hematology Unit, Ospedale S.Giuseppe Empoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Pirrotta","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale S.Giuseppe Empoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Del Rosso","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Ospedale S.Giuseppe Empoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Fontanelli","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale S.Giuseppe Empoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Milandri","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ospedale S.Giuseppe Empoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,22]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214561281"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_3_4_1","doi-asserted-by":"crossref","unstructured":"YangT MoslehiJJ RodenDM.Proarrhythmic effects of ibrutinib a clinically approved inhibitor of Bruton\u2019s tyrosine kinase (BTK) used in cancer therapy [abstract]. Circulation.2015;132(3): (abstract A14587).","DOI":"10.1161\/circ.132.suppl_3.14587"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090126"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-742437"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1457149"},{"key":"e_1_2_3_9_1","unstructured":"Pharmacyclics LLC. [Internet].Imbruvica product monograph.2017. Available from:https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid\u00bc0dfd0279-ff17-4ea9-89be-9803c71bab44"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13290","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T19:33:06Z","timestamp":1721503986000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,22]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/ejh.13290"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13290","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2019,7,22]]},"assertion":[{"value":"2019-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}